FDA approves biologic Tremfya for psoriasis

The U.S. Food and Drug Administration (FDA) has approved Tremfya (guselkumab) as an injection to treat moderate to severe plaque psoriasis in adults. Tremfya is the first approved biologic therapy that targets interleukin-23 – a cytokine, or pro-inflammatory protein, that plays a key role in plaque psoriasis.

Tremfya is a biologic (a drug made in a lab from living cells) that prevents your immune system from going into overdrive and creating an undesired immune response resulting in inflammation. The drug has been proven effective in reducing the symptoms of moderate to severe plaque psoriasis – including itch, pain, stinging, burning and skin tightness – in adults who are candidates for systemic therapy (injections or pills) or phototherapy (treatment using ultraviolet or UV light). 

“The approval of new and effective treatment options is always welcome news for plaque psoriasis patients, as not all patients respond similarly to currently available treatments,” said Michael Siegel, Ph.D., Vice President of Research Programs for the National Psoriasis Foundation. “For the more than one million Americans living with moderate to severe plaque psoriasis, the approval of Tremfya offers physicians and patients an effective new therapy.”

Tremfya received FDA approval based on results from a Phase 3 clinical development program that included more than 2,000 patients. In clinical studies, at 16 weeks, at least seven out of 10 Tremfya-treated patients achieved at least 90 percent clearer skin and more than 80 percent demonstrated cleared or almost cleared skin. 

Nearly nine out of 10 Tremfya-treated patients who achieved a score of 90 on the Psoriasis Area and Severity Index (PASI) at week 28 maintained that response at week 48.  

The data from the clinical development program were presented at the 25th European Academy of Dermatology and Venerology Congress in Vienna, Austria, in October 2016 and the 2017 American Academy of Dermatology Annual Meeting in Orlando, Florida, in March 2017.

Tremfya is manufactured by Janssen Biotech.

 


Driving discovery, creating community

For more than 50 years, we’ve been driving efforts to cure psoriatic disease and improve the lives of those affected. But there’s still plenty to do! Learn how you can help our advocacy team shape the laws and policies that affect people with psoriasis and psoriatic arthritis – in your state and across the country. Help us raise funds to support research by joining Team NPF, where you can walk, run, cycle, play bingo or create your own fundraising event. If you or someone you love needs free, personalized support for living a healthier life with psoriatic disease, contact our Patient Navigation Center. And keep the National Psoriasis Foundation going strong by making a donation today. Together, we will find a cure.

Recent Advance Posts

These new health insurance policies can result in catastrophic out-of-pocket...
LITE study logo
Join our clinical trial researching the effectiveness and safety of home-based...
cartoon red tape and many steps between patient and doctor
NPF’s advocacy team fights for patient-friendly protections in Medicare...
cartoon of health insurance charts, pen, calculator, steth0scope
Selecting a Medicare plan can be overwhelming. Understand which plans cover...
illustration of the brain that looks like a maze
We’re getting closer to understanding chronic pain and its mysterious origins.
Professional wrestler Michael Murray takes his profession and psoriatic disease...
Illustration of diet and exercise icons
NPF's medical board publishes a paper on diet recommendations for people...
Hurricane Florence
Get the latest information about health insurance and prescription drugs if you...
Ready to lace up with Team NPF? Here are 7 simple ways to help you bulletproof...